The p16 (CDKN2a/INK4a) Tumor-Suppressor Gene in Head and Neck Squamous Cell Carcinoma: A Promoter Methylation and Protein Expression Study in 100 Cases

The p16 (CDKN2a/INK4a) gene is an important tumor-suppressor gene, involved in the p16/cyclin-dependent kinase/retinoblastoma gene pathway of cell cycle control. The p16 protein is considered to be a negative regulator of the pathway. The gene encodes an inhibitor of cyclin-dependent kinases 4 and 6...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2003-09, Vol.16 (9), p.944-950
Main Authors: Ai, Lingbao, Stephenson, Krystal K, Ling, Wenhua, Zuo, Chunlai, Mukunyadzi, Perkins, Suen, James Y, Hanna, Ehab, Fan, Chun-Yang
Format: Article
Language:English
Subjects:
Adult
Aged
Alcohol Drinking
Biomarkers, Tumor - analysis
Cancer
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Cell cycle
Cyclin-dependent kinases
DNA Methylation
DNA, Neoplasm - analysis
Epigenetics
Gene inactivation
Genes, p16
Head and Neck Neoplasms - genetics
Head and Neck Neoplasms - mortality
Head and Neck Neoplasms - pathology
Head and neck squamous cell carcinoma
Humans
Immunohistochemistry
Kinases
Middle Aged
Otolaryngology
p16
Pathology
Phase transitions
Phosphorylation
Polymerase Chain Reaction
Prognosis
Promoter hypermethylation
Promoter Regions, Genetic
Protein expression
Proteins
Retinoblastoma
Risk Factors
Smoking
Veterans health care
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The p16 (CDKN2a/INK4a) gene is an important tumor-suppressor gene, involved in the p16/cyclin-dependent kinase/retinoblastoma gene pathway of cell cycle control. The p16 protein is considered to be a negative regulator of the pathway. The gene encodes an inhibitor of cyclin-dependent kinases 4 and 6, which regulate the phosphorylation of retinoblastoma gene and the G1 to S phase transition of the cell cycle. In the present study, p16 gene promoter hypermethylation patterns and p16 protein expression were analyzed in 100 consecutive untreated cases of primary head and neck squamous cell carcinoma by methylation-specific PCR and immunohistochemical staining. The p16 promoter hypermethylation and apparent loss of p16 protein expression were detected in 27% and 74% of head and neck squamous cell carcinoma, respectively. By χ2 test, history of alcohol or tobacco use was significantly correlated with the loss of p16 protein expression (P = .005 and.05, respectively). When patient follow-up data were correlated with various clinical and molecular parameters, tumor size and nodal and clinical stage were the strongest prognostic predictors for disease-free survival (tumor recurrence) and for cause-specific and overall survival in patients with head and neck squamous cell carcinoma. Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression appears to be an independent prognostic factor, although loss of p16 protein may be used to predict overall patient survival in early-stage head and neck squamous cell carcinoma.
ISSN:0893-3952
1530-0285
DOI:10.1097/01.MP.0000085760.74313.DD